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Purpose. Control of persistent pain following spinal surgery is an unmet clinical need. This study compared the efficacy and
safety of buprenorphine transdermal system (BTDS) to oral tramadol/acetaminophen (TA) in Korean patients with persistent,
moderate pain following spinal surgery.Methods. Open-label, interventional, randomizedmulticenter study. Adults with persistent
postoperative pain (Numeric Rating Scale [NRS] ≥ 4 at 14–90 days postsurgery) were enrolled. Patients received once-weekly
BTDS (𝑛 = 47; 5𝜇g/h titrated to 20 𝜇g/h) or twice-daily TA (𝑛 = 40; tramadol 37.5mg/acetaminophen 325mg, one tablet titrated
to 4 tablets) for 6 weeks. The study compared pain reduction with BTDS versus TA at week 6. Quality of life (QoL), treatment
satisfaction, medication compliance, and adverse events (AEs) were assessed. Findings. At week 6, both groups reported significant
pain reduction (mean NRS change: BTDS −2.02; TA −2.76, both 𝑃 < 0.0001) and improved QoL (mean EQ-5D index change:
BTDS 0.10; TA 0.19, both 𝑃 < 0.05). The BTDS group achieved better medication compliance (97.8% versus 91.0%). Incidence of
AEs (26.1% versus 20.0%) and adverse drug reactions (20.3% versus 16.9%) were comparable between groups. Implications. For
patients with persistent pain following spinal surgery, BTDS is an alternative to TA for reducing pain and supports medication
compliance. This trial is registered with Clinicaltrials.gov: NCT01983111.
1. Introduction
Spinal stenosis is a common cause of pain affecting the back
and legs due to narrowing of the spinal canal or neural
foramen. Decompression surgery is often performed to treat
this condition by removing excess bone, thickened ligaments,
degenerate disc material, and other fibrous tissue causing
the stenosis. Sometimes, a fusion procedure is performed
to fuse two adjoining vertebrae together to make the spine
more stable in the case of severe spinal stenosis or unstable
spondylolisthesis [1]. The incidence of spinal stenosis and
other degenerative spine conditions increases with age, and
spinal fusion surgery is often required to treat such condi-
tions. Patients who have undergone lumbar spinal surgery
are vulnerable to adverse consequences from unrelieved or
undertreated postoperative pain after surgery.This is because
pain assessment is often fraught with problems arising from
difficulties in measuring and reporting pain intensity, and,
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in older patients, the presence of cognitive impairment [2].
Inadequate postoperative pain management increases the
risk of complications from the spinal surgery and reduces the
mobility of patients andmay even delay the rehabilitation and
recovery process due to the pain [3]. Major spinal surgery
is associated with moderate-to-severe pain on the first day
after surgery (median score of 7 on the Numeric Rating
Scale [NRS], interquartile range: 5–8) [4]. With analgesic
treatment, pain intensity generally declines from moderate
or severe to mild levels over the first 24–48 h after surgery,
but a proportion of patients may continue to experience
moderate or severe pain beyond this period [5–7]. During
the immediate postoperative period, strong opioid analgesics
may be used for relief of acute pain. Strong opioids are
highly effective and quick-acting inmanaging pain. However,
they have various adverse effects and therefore their benefits
should be weighed against this risk, especially for long-term
use [8].This limits their prolonged use formanaging subacute
pain (1–3 months after surgery) [9] and prompts research
effort to find better and more suitable analgesics for control
of persistent postoperative pain. In particular, the transition
from acute to subacute and chronic pain following surgery
is not well studied, and it has been pointed out that further
attention and research are warranted in this area [10, 11].
Although considered a weak opioid because of its much
lower affinity for the 𝜇-receptor, tramadol may be prescribed
for patients with complicated pain etiology owing to its
dual mechanism of action: binding to 𝜇-receptors as well
as inhibiting serotonin and norepinephrine reuptake in the
central nervous system [12]. Tramadol has a broad range of
therapeutic indications, from acute to chronic pain, and has
been used as a first-line treatment in musculoskeletal system
disorders, for relief of persistent postoperative pain, as well
as various types of chronic pain [13]. However, oral formu-
lations of tramadol have a number of systemic side-effects
such as headache, sleep disturbance, constipation, vomiting,
hydrodipsomania, sweating, nausea, and dizziness [14] and,
like other opioids, prolonged use may be associated with
dependence and abuse [15]. To manage persistent postopera-
tive pain, opioid analgesics such as tramadol have been used
together with non-opioid analgesics such as acetaminophen
to enhance their analgesic effects and improve quality of life
(QoL) for patients [13, 16, 17].
Buprenorphine is a synthetic opioid analgesic used in the
management of postoperative pain. A review of the buprenor-
phine transdermal patch found that it was as effective as
other opioids such as oralmorphine, oxycodone, and fentanyl
in relieving pain and that buprenorphine could be used to
achieve the same effect at lower dose equivalents [18]. Studies
in patients with chronic postoperative pain suggest that CNS
sensitization is also reduced or absent with buprenorphine
compared with other agents [19]. Buprenorphine can be
administered via various routes. A once-weekly patch for
transdermal application is available as a dosing regimen that
can maintain an analgesic effect equivalent to tramadol [20].
While the buprenorphine transdermal system (BTDS) has
been investigated in a number of studies and, in particular, for
the management of chronic pain [18, 21–23], its efficacy and
safety for the relief of persistent postoperative subacute pain
have not been extensively studied.Owing to the slower-acting
pharmacological profile of buprenorphine, BTDS cannot be
used for immediate pain relief or as a substitute for short-
acting analgesics [19], but may have potential for use in
managing persistent postoperative pain. For patients with
multiple comorbidities who face an increasing number of
orally administered drugs, the use of once-weekly BTDS
offers the potential benefits of reduced pill burden and greater
convenience.
In a proportion of patients, postoperative pain can be
serious and may persist for prolonged periods (several weeks
up to several months) [24]. Achieving adequate postop-
erative pain control remains an unmet need during the
subacute phase, where pain is present for at least 6 weeks
but less than 3 months [25]. Research on the use of anal-
gesics for subacute pain is limited, and a literature search
revealed no studies comparing transdermal buprenorphine to
oral tramadol/acetaminophen for the treatment of subacute
postoperative pain. This study reports on a comparison
of transdermal buprenorphine (BTDS) treatment with oral
tramadol/acetaminophen (TA) for reducing pain in patients
with persistent postoperative pain following lumbar spinal
surgery.
2. Materials and Methods
This was a multicenter, open-label, interventional, random-
ized, noninferiority study conducted at 8 medical institutions
in South Korea. It was conducted in accordance with Korea
Good Clinical Practice (KGCP) [26] and International Con-
ference on Harmonisation (ICH) [27] guidelines, complied
with the rights and safety of subjects under the Declaration
of Helsinki, and was approved by the Institutional Review
Boards (IRB) of all eight institutions. All patients provided
written informed consent prior to participating in the study.
2.1. Study Design. The study had two arms: the BTDS group
which received the study drug, buprenorphine transdermal
patch (NORSPAN), and the TA group which received the
comparator drug, tramadol 37.5mg/acetaminophen 325mg
tablet (Ultracet ER Semi Tab), which is commonly used in
Korea (Figure 1). There were 3 visits: Visit 1 (baseline, at week
0: 14–90 ± 4 days after surgery), Visit 2 (week 2 ± 4 days),
and Visit 3 (week 6 ± 8 days), as shown in Figure 1. At Visit 1,
patients were randomized (1 : 1) to receive either BTDS or TA,
based on computer-generated randomization lists.The initial
dose (baseline) for BTDS was 5 𝜇g/h for 7 days and this was
increased to 10, 15, or 20𝜇g/h during the study, depending
on the subject’s pain intensity and at the discretion of the
investigator. The initial dose for the TA group was 1 tablet
twice daily and was increased to 2, 3, or 4 tablets twice daily
depending on the subject’s pain intensity and at the discretion
of the investigator.The rescue medication, when needed, was
celecoxib (Celebrex 200mg capsules).
2.2. Patients. The study enrolled patients aged ≥20 years who
had lumbar fusion surgery (1-2 level fusion) and experienced
persistent pain (numerical rating scale, NRS [28] ≥ 4, 0–10
points, with 0 points = no pain, mild pain = 1–3, moderate
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Treatment perio＞1
Transdermal buprenorphin？2 (±celecoxib)
Visit 3Visit 2Visit 1 (baseline)
Tramadol/acetaminophen3 (±celecoxib)
Week 6 ± 8 daysWeek 2 ± 4 days14 − 4 to 90 + 4 days
aer surgery
Surgery Screening/randomization
Figure 1: Study design and visit schedule. 1Unscheduled visits could be conducted at any time during the treatment period. Domperidone
maleate was concurrently prescribed for 2 weeks from initiation of the study drug administration. Subsequently, continued use was
determined at the discretion of the investigator. 2Permitted study drug dose escalation: transdermal buprenorphine (BTDS) 5𝜇g/h to 10 𝜇g/h
to 15 𝜇g/h or 20 𝜇g/h. 3Permitted comparator drug dose escalation: tramadol/acetaminophen (TA; tramadol 37.5mg/acetaminophen 325mg)
1 tablet × 2 doses per day to 2 tablets × 2 doses per day to 3 tablets × 2 doses per day or 4 tablets × 2 doses per day. BTDS: buprenorphine
transdermal system (NORSPAN); TA: tramadol/acetaminophen.
pain = 4–6, and severe pain = 7–10) 14–90 days after
surgery. Key exclusion criteria included use of strong opioids,
buprenorphine or tramadol/acetaminophen < 1 week prior to
trial participation; current use of CNS depressants or muscle
relaxants; postoperative complications; symptoms of acute
pain after lumbar fusion or a pain relief profile characterized
by rapidly changing analgesic requirements; major pain not
attributable to spinal disease; ongoing anticancer treatment
that could affect pain assessment; clinically significant res-
piratory, cardiovascular, renal, or hepatic impairment; any
hypersensitivity, allergy, or other contraindication to the use
of buprenorphine, tramadol/acetaminophen or celecoxib, or
domperidone; administration of other investigational prod-
ucts at enrollment or within 30 days of trial participation;
history of drug abuse or medical history of narcotic or
drug dependence. Pregnant women or those of childbearing
potential who were unwilling or unable to use appropriate
contraception during the study were also excluded.
Informed patient consent was obtained prior to the
start of study. All demographic information, medical history,
physical examination, and vital signs were recorded. Body
temperature, pulse, and blood pressure were measured at
every visit and clinical laboratory tests were conducted at
Visits 1 and 3. Pregnancy tests were conducted for women
of childbearing potential at Visits 1 and 3 with a human
chorionic gonadotropin (hCG) urine test.
2.3. Study Assessments
2.3.1. Pain Intensity. Subjects were asked to indicate the
intensity of pain symptoms using NRS over the last 24 hours
at every visit. At Visit 1 (baseline), pain assessment was
conducted prior to investigational product administration.
The primary efficacy evaluation was based on the change
in the pain intensity from baseline to Visit 3 (week 6).
Noninferiority of BTDS to TA for pain reduction at week 6
was evaluated.
2.3.2. Quality of Life and Treatment Satisfaction. At baseline
and week 6, subjects were also asked to assess their health-
related quality of life (QoL) using the EuroQol Group
5-Dimension Self-Report Questionnaire (EQ-5D-3L [29],
Korean version), consisting of 5 items, that is, mobil-
ity, self-care, usual activities, pain/discomfort, and anxi-
ety/depression. Each item was evaluated at 3 levels. The total
EQ-5D index scorewas computed using a score table (Table 1)
as follows: 1 − 0.081 − (score according to item and level) −
0.269 (if there is at least one Level 3 item).
AtWeek 2 andWeek 6, investigators evaluated the overall
satisfaction with treatment using a 7-point Clinical Global
Impression of Change scale (CGIC, 1 = very much improved
to 7 = very much worse) [30, 31]. At the same time-points,
subjects were also asked to evaluate their overall satisfaction
with the treatment since the last visit using a 7-point Patient
Global Impression of Change [32] scale (PGIC, 1 = very
much improved to 7 = very much worse). The changes from
baseline toweek 6 in the EQ-5D,CGIC, andPGIC scoreswere
calculated.
2.3.3. Medication Use and Compliance. Subjects were
instructed to return all unused medication at every visit.
Actual dosing was determined by comparing the amount
of unused study or comparator drug returned by the
subject against the prescribed dose. The final dose of the
investigational product at week 6 was also compared to the
initial dose at baseline. The compliance rate was computed
as the “total number of doses actually administered/total
number of doses prescribed.” A compliance rate of ≥80%was
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Table 1: Computation of EQ-5D index score.
Itema Level 1 Level 2 Level 3
Mobility 0 0.069 0.314
Self-care 0 0.104 0.214
Usual activities 0 0.036 0.094
Pain/discomfort 0 0.123 0.386
Anxiety/depression 0 0.071 0.236
aMobility: Level 1: I have no problems in walking around; Level 2: I have
some problems in walking around; Level 3: I am confined to bed. Self-care:
Level 1: I have no problems with self-care; Level 2: I have some problems
taking a bath/shower, or dressing myself; Level 3: I am unable to take a
bath/shower, or dress myself. Usual activities: Level 1: I have no problems
with performing my usual activities; Level 2: I have some problems with
performing my usual activities; Level 3: I am unable to perform my usual
activities. Pain/discomfort: Level 1: I have no pain or discomfort; Level
2: I have moderate pain or discomfort; Level 3: I have extreme pain or
discomfort. Anxiety/depression: Level 1: I amnot anxious or depressed; Level
2: I am moderately anxious or depressed; Level 3: I am extremely anxious or
depressed.The EQ-5D index (total score) was computed as follows: 1 − 0.081
− (score according to item and level) − 0.269 (if there was at least one Level
3 item).
deemed acceptable. The total administered dose of rescue
medication (celecoxib) for each group was computed as
total number of doses of rescue medication administered ×
200mg.
2.3.4. Safety. Subjects were asked to report all adverse events
(AEs). This information was also obtained from the subject
via interview during scheduled visits in the study period.The
AE information included the onset and resolution dates, AE
severity, action taken and outcome, and causal relationship
with the investigational product or suspected drugs other
than the investigational product.
2.4. Statistical Analysis. Noninferiority of BTDS to TA in
terms of pain intensity reductionwas evaluated by comparing
the lower limit of the one-sided 97.5% confidence interval
(CI) for the between-group difference in the change in pain
scores from baseline to week 6 with a prespecified margin
of 1.5, as described by Karlsson and Berggren [20]. In that
study, which compared BTDS with tramadol in patients with
chronic osteoarthritis pain, themean pain score (on the BS-11
scale [33]; range 0–10) for tramadolwas 6.39± 1.58 at baseline;
and after 12 weeks of treatment, the mean score decreased to
3.80 ± 2.20, giving a change of −2.59 ± 2.20 units [20]. Sample
size estimation was performed accordingly: in order to detect
differences with≥90% power at a level of significance of 0.025
(one-sided), the sample size was computed as 47 subjects per
group. Allowing for a dropout rate of 30%, it was estimated
that 68 subjects would need to be randomized to each of
the 2 treatments (total of 136 subjects). Notwithstanding
some differences in study duration and patient population,
estimates from [20] were used in designing the present study,
as it appeared the most similar in terms of treatments and
pain context (BTDS versus tramadol in nonacute pain).
The full analysis set (FAS), that is, patients who received
at least one dose of study or comparator treatment, was used
for the efficacy andQoL analyses and supported by additional
analyses on the per-protocol (PP) set, that is, patients who
completed the study without major protocol deviations. The
FAS was also used for medication use and compliance analy-
ses. Safety analysis was performed on the enrolled patients,
that is, safety set (SS: patients who received the study or
comparator treatment and had at least 1 safety assessment).
The mean and SD were calculated for continuous data such
as patient demographics, health condition, pain intensity
(NRS), and EQ-5D, CGIC, and PGIC scores. 𝑇-tests were
used to evaluate the significance of mean differences between
the BTDS and TA groups where assumptions of normality
were met. Otherwise, the Wilcoxon rank sum tests were
used. Paired 𝑡-tests were used to evaluate the significance of
changes in pain score from baseline at each visit for the BTDS
and TA groups. Categorical data were summarized with fre-
quencies and percentages and the Chi-square test or Fisher’s
exact test was used to evaluate the significance of between-
group differences. All statistical analyses were performed
using SAS statistical analysis software (SAS Institute, Cary,
NC, USA, version 9.4). Except for noninferiority analysis,
statistical significance was evaluated at the 0.05 level.
3. Results
The study was conducted from Oct 2013 to Nov 2014. A
total of 138 patients were screened. Of these, 2 withdrew
consent and the remaining 136 patients were randomized for
treatment. Two subjects failed to receive the investigational
treatments. The SS thus consisted of 134 subjects (69 in the
BTDS group, 65 in the TA group) who received the study
or comparator treatment and had at least 1 safety assessment
(Figure 2). Another 26 subjects were excluded from the
FAS. The reasons for exclusion and corresponding number
of subjects are provided in Figure 2. A total of 87 subjects
completed the study (PP set): 47 in the BTDS group and 40
in the TA group.
Subject characteristics and coexisting medical conditions
for the SS are shown in Table 2. There were no significant
differences between the BTDS and TA groups in terms of
patient characteristics (𝑃 > 0.05 for all; Table 2). The average
age for the BTDS group was 64.4 ± 10.8 years and 61.5 ± 9.0
years for the TA group. About 4 in 10 subjects were males. On
average, subjects were enrolled approximately 20 days after
undergoing lumbar fusion surgery.
3.1. Pain Intensity Scores. On average, patients in both groups
reported reduction in pain intensity from “moderate” at
baseline (mean NRS: BTDS 5.04 ± 0.82; TA 5.24 ± 0.84) to
“mild” at week 6 (mean NRS: BDTS 2.73 ± 1.86; TA 2.49
± 1.40). At week 2 and at week 6, mean NRS scores were
significantly lower than at baseline in both BTDS and TA
groups (𝑃 < 0.0001 for all) (Figure 3). The mean NRS
reductions from baseline at week 6 (last observation carried
forward, LOCF) were 2.02 ± 2.14 units for the BTDS group
and 2.76 ± 1.45 units for the TA group.
At week 6, the between-group difference in mean NRS
reduction was 0.74 and the lower limit of the one-sided 97.5%
CI of thatmeanwas−1.45 (>−1.5), indicating that BTDS is not
inferior to tramadol/acetaminophen for pain reduction. The
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(i) Serious AE (1)
(ii) Nonserious AE (2)
(iii) Informed consent withdrawal (5)
(iv) Use of prohibited concomitant
medication (1)
(v) Visit window violation (1)
Excluded from Per-protocol set, n = 10
(i) Informed consent withdrawal (2)
(ii) Use of prohibited concomitant
medication (2)
Excluded from Per-protocol set, n = 11
(i) No primary ecacy
assessment (5)
(ii) Inclusion/exclusion criteria
violations (8)
assessment (13)
(iii) No/unclear primary endpoint
Excluded from FAS, n = 26
Failed to administer
investigational drug
n = 2
BTDS PP set
n = 47
BTDS group
n = 57
TA group
n = 51
TA PP set
n = 40
Full analysis set
n = 108
Safety set
n = 134
Randomized to treatment
n = 136
Withdrew consent
n = 2
Screened
N = 138
(iii) Medication complianc？ < 80% (7)
Figure 2: Flow of patients through the trial. FAS: full analysis set; BTDS: buprenorphine transdermal system (NORSPAN); TA: tramadol/acet-
aminophen.
results for the PP analysis were also in agreement: the mean
between-group difference was 0.43 and lower limit of the CI
was −1.20 (>−1.5).
3.2. Quality of Life and Treatment Satisfaction Scores. Table 3
shows the QoL (EQ-5D-3L) and treatment satisfaction scores
(CGIC and PGIC). At week 6, the improvement in mean EQ-
5D index scores from baseline was significant for both BTDS
and TA groups (𝑃 < 0.05 for both). The TA group reported
a greater improvement in the EQ-5D index score than the
BTDS group (𝑃 = 0.0258). For individual EQ-5D dimension
items, significant improvements were seen for “self-care” and
“usual activities” for both groups and in “pain/discomfort” for
the TA group.
Overall, subjects assessed their condition as somewhat
improved after treatment. At week 6, mean CGIC scores in
the BTDS and TA groups were 2.28 ± 1.21 and 2.43 ± 1.01,
respectively (Table 3). There were no significant between-
group differences in terms of treatment satisfaction as
assessed by both investigators and subjects at week 6.
3.3. Medication Use and Compliance. Table 4 presents med-
ication use and compliance data for the FAS. At Week 2
and Week 6, the BTDS group had a statistically significantly
higher compliance rate than the TA group (𝑃 = 0.078 and
<0.0001, resp.).
Overall, 16% of subjects had a dose increase during the
study period: 9 subjects from the BTDS group had their dose
increased from 5 𝜇g/h to 10 𝜇g/h; and 8 subjects from the
TA group had their dose increased from 1 tablet twice daily
to 2 tablets twice daily. There were no significant between-
group differences in the total dosage of rescue medication
used, either in the 2 weeks from baseline to week 2, or in the
rest of the study period, from week 2 to week 6.
3.4. Adverse Events. The incidence of adverse events was
similar in the 2 groups, being 26.1% (18/69 subjects, 31 events)
in the BTDS group and 20.0% (13/65 subjects, 22 events) in
the TA group (𝑃 = 0.4037); and similarly for the incidence of
serious adverse events: 4.4% (3/69 subjects, 3 events) in the
BTDS group while no serious adverse event was reported in
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Table 2: Patient characteristics and medical conditions.
Safety set
Buprenorphine
transdermal system
(𝑛 = 69)
Oral
tramadol/acetaminophen
(𝑛 = 65)
𝑃 valuea
Sex, male, 𝑛 (%) 25 (36.2) 29 (44.6) 0.3228
Age, mean ± SD, years 64.4 ± 10.8 61.5 ± 9.0 0.0969
Age distribution, 𝑛 (%)
≥70 years, 𝑛 (%) 24 (34.8) 11 (16.9)
0.063760–69 years, 𝑛 (%) 27 (39.1) 30 (46.1)
50–59 years, 𝑛 (%) 12 (17.4) 20 (30.8)
<50 years, 𝑛 (%) 6 (8.7) 4 (6.1)
Weight (baseline), mean ± SD, kg 62.2 ± 9.4 62.0 ± 10.2 0.9176
Period after lumbar fusion surgery, mean ± SD, days 20.9 ± 11.8 19.2 ± 9.5 0.3532
10 days to <1 month, 𝑛 (%) 61 (88.4) 57 (87.7) 0.8987
≥1 month, 𝑛 (%) 8 (11.6) 8 (12.3)
History of medical or allergy condition over past 2
years, 𝑛 (%) 55 (79.7) 57 (87.7) 0.2125
Used prior medication within 4 weeks of baseline visit,
𝑛 (%) 68 (98.6) 64 (98.5) 1.0000
Had ≥1 dose of analgesics or drugs with analgesic effect
during the study, other than study or rescue medication 7 (10.1) 7 (10.8) 0.9060
aChi-square or Fisher’s exact test.
BTDS
TA
20 6
Weeks on treatment
0
2
4
6
8
Pa
in
 in
te
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ity
 (N
RS
)
Figure 3: Mean pain intensity scores from baseline to Week 6.
BTDS: buprenorphine transdermal system (NORSPAN); TA: tra-
madol/acetaminophen; NRS: numerical rating scale.
the TA group (𝑃 = 0.2450) (Table 5).There was no significant
between-group difference in the incidence rate for adverse
drug reactionswhere a causal relationwith the investigational
product could not be ruled out (20.3% versus 16.9%, 𝑃 =
0.6171).
In both groups, the most commonly reported AE was
gastrointestinal disorders, mainly nausea and constipation
(see Table 6, and Supplementary Table S1, in Supplemen-
tary Material available online at https://doi.org/10.1155/2017/
2071494, for a detailed list of adverse events). Four subjects
receiving BTDS reported general disorders including patch
administration site conditions (5 events: administration site
pruritus [3 events] and administration site erythema [1
event]), while 3 subjects receiving TA had elevated liver
enzymes (AST, ALT; 6 events). Two serious AEs were
reported in the BTDS group: “postprocedural infection” at
2.90% (2/69 subjects, 2 events) and “arthralgia” at 1.45% (1/69
subjects, 1 event); no SAEs were reported in the TA group.
No serious adverse drug reactions were reported. All adverse
events were of grade 1 (mild) or 2 (moderate) in severity.
There were no adverse events of grade 3 (severe) or above.
4. Discussion
Patients who undergo instrumented spinal fusion and
decompression surgery often suffer from severe postoperative
pain, which may persist for several weeks [34]. To our
knowledge, this study is the first to report on the use of
the buprenorphine transdermal patch to manage subacute
pain in the 1–3-month period following surgery. In our
study, both BTDS and TA reduced the intensity of persistent
postoperative pain from “moderate” to “mild” after 6 weeks
of treatment. BTDS has been shown elsewhere to be effective
for pain control for at least 3 months without significant dose
increase [18]. There were no significant differences between
the BTDS and TA groups in terms of the incidence of adverse
events or adverse drug reactions. For the BTDS group, the
most common AEs were gastrointestinal events (including
nausea, constipation, and vomiting) and skin reactions at
the patch site (including pruritus and erythema). The safety
profile for BTDS in this study was consistent with earlier
studies on the long-term use of buprenorphine for patients
suffering chronic pain [20, 23].
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Table 3: Quality of life and treatment satisfaction scores.
Full analysis set
Buprenorphine
transdermal system
(𝑛 = 47)
Oral
tramadol/acetaminophen
(𝑛 = 40)
𝑃 value
(𝑇-test)
EQ-5D indexa, mean ± SD
Baseline (week 0) 0.57 ± 0.13 0.46 ± 0.27 —
Week 6 (LOCF) 0.68 ± 0.18 0.65 ± 0.14 —
Improvement (week 0 to week 6) 0.10 ± 0.19 0.19 ± 0.21 0.0258
𝑃 value (paired 𝑡 test) 0.0004 <0.0001 —
EQ-5D-3L dimension scores
(1) Mobility
Baseline (week 0) 0.86 ± 0.08 0.85 ± 0.11 0.7111
Week 6 (LOCF) 0.89 ± 0.03 0.88 ± 0.03 0.6256
Improvement (week 0 to week 6) 0.03 ± 0.08 0.03 ± 0.11 0.8326
𝑃 value (paired 𝑡 test) 0.0080 0.0281
(2) Self-care
Baseline (Week 0) 0.83 ± 0.07 0.78 ± 0.14 0.0161
Week 6 (LOCF) 0.87 ± 0.05 0.84 ± 0.07 0.0108
Improvement (week 0 to week 6) 0.04 ± 0.08 0.06 ± 0.13 0.3247
𝑃 value (paired 𝑡 test) 0.0008 0.0021
(3) Usual activities
Baseline (week 0) 0.88 ± 0.01 0.82 ± 0.14 0.0007
Week 6 0.89 ± 0.02 0.89 ± 0.05 0.6431
Improvement (Week 0 to Week 6) 0.01 ± 0.01 0.07 ± 0.13 0.0006
𝑃 value (paired 𝑡 test) 0.0019 0.0002
(4) Pain/discomfort
Baseline (week 0) 0.80 ± 0.02 0.78 ± 0.10 0.1245
Week 6 (LOCF) 0.81 ± 0.09 0.82 ± 0.05 0.6831
Improvement (week 0 to week 6) 0.01 ± 0.09 0.04 ± 0.12 0.1731
𝑃 value (paired 𝑡 test) 0.2940 0.0158
(5) Anxiety/depression
Baseline (Week 0) 0.88 ± 0.04 0.88 ± 0.08 0.8932
Week 6 (LOCF) 0.89 ± 0.07 0.90 ± 0.03 0.5537
Improvement (week 0 to week 6) 0.01 ± 0.08 0.02 ± 0.07 0.6613
𝑃 value (paired 𝑡 test) 0.1865 0.0479
Treatment satisfaction scores at week 6, mean ± SD
CGICb 2.46 ± 1.28 2.37 ± 0.98 0.7067
PGICb 2.53 ± 1.28 2.39 ± 0.92 0.5304
aQuality of life (EQ-5D-3L, Korean version): consists of 5 items, that is, mobility, self-care, normal activities, pain/discomfort, and anxiety/depression. EQ-
5D-3L scores were computed according to Table 1; bCGIC, PGIC: Clinical Global Impression of Change, Patient Global Impression of Change. 1 = very much
improved since the initiation of treatment; 2 =much improved; 3 =minimally improved; 4 = no change frombaseline (the initiation of treatment); 5 =minimally
worse; 6 = much worse; 7 = very much worse since the initiation of treatment. 푃 values < 0.05 are marked in bold text.
Both clinicians and subjects assessed their condition as
somewhat improved since the start of treatment; the extent
of improvement was similar in the BTDS and TA groups.
Importantly, subjects reported significant improvements in
the “self-care” and “usual activities” EQ-5D dimensions,
suggesting that they felt better able to manage their usual
activities on their own after 6 weeks of treatment.
The management of persistent postoperative pain is
associated with a number of challenges. Achieving adequate
pain control is important to limit the negative effects of
persistent postoperative pain, but inappropriate use of strong
opioids to manage pain is associated with a risk of tolerance
and abuse [35] and, in the elderly, delirium and cognitive
decline [36]. The results of a systematic review on long-term
opioid management of chronic noncancer pain suggest that
many patients discontinue treatment due to adverse events
or insufficient pain relief [37]. Certain groups of patients may
be particularly affected by the adverse side-effects of opioids,
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Table 4: Medication compliance rate, dose change, and use of rescue medication.
Full analysis set
Buprenorphine
transdermal system
(𝑁 = 57)
Oral
tramadol/acetaminophen
(𝑁 = 51)
𝑃 value
Medication compliance rate∗, %, mean ± SD
At Week 2 97.9 ± 10.1 92.5 ± 21.1 0.0078†
At Week 6 97.8 ± 14.1 91.0 ± 18.9 <0.0001†
Dose change of study medication
Patients requiring dose change during study, 𝑛 (%) 9 (15.8) 8 (15.7) —
Week 6 dose of patients who had dose change 10 𝜇g/h 2 tablets —
Dose change, mean ± SD 0.79 ± 1.84𝜇g 0.16 ± 0.37 tablets —
Total dose of rescue medication, mg, mean ± SD
Baseline to week 2 (2-week duration) 1,439.2 ± 1,741.3 1,412.2 ± 2,009.7 0.9429‡
Week 2 to week 6 (4-week duration) 1,534.7 ± 1,820.0 1,869.4 ± 2,530.0 0.4542‡
∗Medication compliance rate = total number of doses actually administered (actual number of medication days)/total number of doses prescribed (number of
medication days prescribed); †Wilcoxon rank sum test; ‡푇-test.
Table 5: Adverse events.
Safety set Group Subjects, 𝑛 Number ofevents, 𝑛 Incidence, 𝑛 (%)
95% CI (lower,
upper) 𝑃 value
Adverse events (AE)
BTDS 69 31 18 (26.1) (15.7, 36.5) 0.4037a
TA 65 22 13 (20.0) (10.3, 29.7)
Total 134 53 31 (23.1) (16.0, 30.3)
Serious adverse event (SAE)
BTDS 69 3 3 (4.4) (0.0, 9.2) 0.2450b
TA 65 0 0 (0) —
Total 134 3 3 (2.2) (0.0, 4,7)
Adverse drug reaction (ADR)
BTDS 69 19 14 (20.3) (10.8, 29.8) 0.6171a
TA 65 13 11 (16.9) (7.8, 26.0)
Total 134 32 25 (18.7) (12.1, 25.3)
Withdrawals due to AE
BTDS 69 5 4 (5.8) (0.3, 11.3) 0.1201b
TA 65 0 0 (0) —
Total 134 5 4 (3.0) (0.1, 5.9)
aChi-square test; bExact test; BTDS: buprenorphine transdermal system; TA: tramadol/acetaminophen.
and may require proactive management [38]. For example,
opioid doses for older patients may have to be reduced to
half of the standard adult dose in order to limit adverse
events while maintaining an adequate level of analgesia [8].
Buprenorphine, on the other hand, does not require dose
adjustments for those with impaired renal function or for
the elderly [39]. In this study, subjects who received BTDS
reported mainly gastrointestinal-related adverse events such
as nausea and constipation. These side-effects are typical of
opioid analgesics, though rates of constipation associated
with buprenorphine are reported to be lower than for other
opioids [22]. Other commonly reported events for patients
receiving BTDS included erythema (𝑛 = 1; 1.5%) or pruritus
(𝑛 = 3; 4.4%) at the patch application site (reported in
the “General disorders and administration site conditions”
category, Table 6; Supplementary Table S1). Application site
reactions are commonly reported with other transdermal
opioid formulations, for example, fentanyl patches. Respi-
ratory depression is a potentially life-threatening adverse
event associated with use of opioids. However, the risk
of respiratory depression is lower with buprenorphine due
to its “respiratory ceiling” effects [22]. The dose against
time effect plot for intravenous buprenorphine exhibits a
“ceiling” at doses ≥ 0.2mg. This “ceiling effect,” coupled with
the lack of apnea at high doses, makes buprenorphine a
much safer drug to use. At steady state, elderly (≥75 years)
and younger (50–60 years) patients who were systemically
exposed to buprenorphine showed similar efficacy and safety
profiles despite the expected age-related pharmacodynamic
and pharmacokinetic differences in physiology [39, 40].
Some limitations of our study should be considered when
interpreting the results. Increase in pain medication dose
was permitted during the study, similar to normal clinical
practice, in which doses would be adjusted for individual
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Table 6: Adverse events by system organ class.
Safety set
Buprenorphine transdermal
system Oral tramadol/acetaminophen Total
Subjects
(𝑁 = 69) Events
Subjects
(𝑁 = 65) Events
Subjects
(𝑁 = 134) Events
Gastrointestinal disorders 12 (17.4) 14 9 (13.9) 9 21 (15.7) 23
General disorders and administration site
conditions 4 (5.8) 5 1 (1.5) 1 5 (3.7) 6
Nervous system disorders 4 (5.8) 4 — — 4 (3.0) 4
Musculoskeletal and connective tissue
disorders 3 (4.4) 4 1 (1.5) 1 4 (3.0) 5
Investigations 1 (1.5) 1 3 (4.6) 6 4 (3.0) 7
Skin and subcutaneous tissue disorders — — 3 (4.6) 3 3 (2.2) 3
Infections and infestations 2 (2.9) 2 1 (1.5) 1 3 (2.2) 3
Cardiac disorders — — 1 (1.5) 1 1 (0.8) 1
Injury, poisoning and procedural
complications 1 (1.5) 1 — — 1 (0.8) 1
𝑇𝑜𝑡𝑎𝑙푎 18 (26.1) 27 13 (20.0) 22 31 (23.1) 53
aAll adverse events were of severity grades 1 (mild) or 2 (moderate). There were no adverse events of severity greater than grade 3 (severe).
patients to achieve an acceptable level of pain control. How-
ever, the equivalent efficacy of initial doses for the study and
control treatments could not be determined at the outset. We
therefore selected the lowest available doses (i.e., 5 𝜇g/hBTDS
and 1 tablet of tramadol 37.5mg/acetaminophen 325mg twice
daily).We also note that the possibility of dose increases could
make it more difficult to interpret comparisons between the
groups. Nevertheless, the observed proportion of subjects
with a dose increase was very similar in the 2 groups (BTDS:
17.5%; TA: 17.0%). Moreover, the actual dose increases in
both groups were modest, from 5 𝜇g/h to 10 𝜇g/h for BTDS
and from 1 tablet twice daily to 2 tablets twice daily for
TA. Only 8 subjects in the BTDS group and 7 in the TA
group had their prescribed pain medication up-titrated even
though there were many subjects with moderate pain in the
second week (mean NRS scores were 3.9 ± 1.6 and 3.5 ± 1.6,
resp.). This implies that active up-titration of the medication
dose may not have taken place for some subjects. For BTDS,
it is possible that the longer dosing interval and slower
titration (no more than once every 7 days) could have led
to fewer subjects having their medication up-titrated. These
characteristics should be taken into account when designing
future studies involving BTDS therapy. Despite the small
number of up-titration cases, the mean NRS scores recorded
at week 6 were below 3 for both treatments (BTDS 2.7 ± 1.9;
TA 2.5 ± 1.5), which is considered a meaningful level of pain
control [41].
A limitation of a nonblinded design is the potential
for bias in subjective assessments even when an active
comparator is used. As the aim was to evaluate the strengths
and weaknesses of the treatments under normal clinical use
and according to product prescribing information, an open-
label active-control study design was selected. The different
characteristics of the 2 treatments (e.g., administration route,
dosing interval, and speed of titration)may have implications
for patient preference and compliance and would need to be
taken into consideration by physicians when individualizing
treatment for patients. As transdermal buprenorphine is not
recommended for patients with rapidly changing analgesic
requirements, subjects with severe or unstable pain would
have been underrepresented in this study. Thus, our conclu-
sions may not be generalizable to patients with more severe
pain.
While both groups of subjects showed statistically sig-
nificant improvement in most of the parameters evalu-
ated, the compliance rate was higher among subjects using
the buprenorphine patch than among those receiving tra-
madol/acetaminophen tablets. Similar observations were
made by Lovborg et al. in their review of transdermal opioid
patches [42]. All subjects who received the BTDS patch met
the minimum compliance rate of 80% at the end of 6 weeks;
7 subjects in the TA group were excluded from the PP set for
poor compliance, leading to a lower than expected number
of subjects in the TA group completing the study without
protocol deviations. This result suggests that the use of a
once-weekly transdermal patch may be more convenient for
prolonged use compared to twice-daily tablets, especially in
older patients who have coexisting medical conditions and
are concurrently on multiple oral medications. For these
patients, the buprenorphine patch system does not add to the
number of pills to be taken daily and can help to improve
compliance when the medication has to be taken for several
weeks.
5. Conclusions
The buprenorphine transdermal system was comparable to
oral tramadol/acetaminophen in reducing pain intensity after
6 weeks of treatment in patients with persistent moderate
postoperative pain at 1–3months after spinal surgery. Patients
treated with BTDS also had better compliance to the pre-
scribed treatment.
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